Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data iBio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
0.39
0.44
2.02
1.64
2.37
1.88
0
0.23
0.4
0.1
Cost of revenue
0.7
1.46
0.22
Gross profit
0.94
0.91
2.17
Research and development
4.12
3.99
5.47
3.57
9.99
9.83
10.3
5.19
8.31
19.6
General and administrative
10.6
10.7
12.3
11.4
22
21.8
19
11.7
10.7
10.6
Operating expenses
14.7
14.7
17.8
14.9
32
31.6
29.3
16.9
19
35.2
Operating income
-14.3
-14.2
-15.8
-14
-31.1
-29.7
-29.3
-16.6
-18.6
-35.1
Interest expense
1.93
1.92
1.9
2.47
2.45
1.41
0.08
0.17
0.21
0.05
Interest income
0.04
0.02
0.08
0.02
0.14
0.18
0.21
0.36
0.44
2.15
Other non-operating income
-1.87
-1.88
-1.81
-2.44
7.9
0.18
0.03
1.19
0.23
2.1
Pre-tax income
-18.4
-33
Income tax
0
0
0
0
0
0
0
0
0
0
Income from continuing operations
-29.5
-29.3
Net income to minority interests
-1.61
-0
-0
-0.01
-0.01
-0
Net income
-14.5
-16.1
-17.6
-16.4
-23.2
-50.3
-65
-24.9
-18.4
-33
EBITDA
-12.9
-12.9
-15.6
-13.7
-30.6
-27.4
-28.7
-16
-18.1
-34.6
EPS, basic
-819.92
-769.93
-469.96
-304.97
-59.99
-115.59
-106.19
-6.50
-1.75
-0.32
EPS, diluted
-819.92
-769.93
-469.96
-304.97
-59.99
-115.59
-106.19
-6.50
-1.75
-0.32
Shares, basic (weighted)
0.02
0.02
0.04
0.13
0.39
0.44
0.61
3.83
10.5
104
Shares, diluted (weighted)
0.02
0.02
0.04
0.13
0.39
0.44
0.61
3.83
10.5
104
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
15.9
4.42
4.42
55.1
77.4
22.7
4.3
14.2
8.58
56.4
Short-term investments
0
0
31.6
Receivables
0.18
0.08
0.1
0.08
0.43
1
0
0
Inventory
0.03
3.9
0
0
Other current assets
0.28
0.28
0.29
0.21
2.07
1.55
0.66
0.75
1.03
3.08
Total current assets
8.57
16.3
4.81
61.7
105
45.1
26.3
15.7
9.72
92.2
Property, plant and equipment
25.6
25.2
24.4
3.66
8.63
1.37
4.22
3.63
3.16
3.09
Lease right-of-use assets
0
3.07
2.72
2.4
2.05
1.67
Intangible assets
1.82
1.62
1.37
1.14
0.95
4.85
5.39
5.37
6.85
1.83
Total assets
36
43.1
30.6
94.2
147
99.4
41.2
28.7
23.2
99.1
Accounts payable
0.75
0.79
1
1.76
2.25
4.26
1.85
0.36
2.19
4.42
Accrued liabilities
0.92
1.05
0.97
1.11
3
3.76
4.56
2.03
1.35
5.63
Deferred revenue
0
1.28
1.81
0.42
0.1
0
0.2
1.2
1.15
Total current liabilities
2.01
2.04
3.46
5.24
6.65
30.4
22.1
3.84
6.11
11.7
Long-term debt
0
0.34
0
0.77
Lease liabilities
0
3.51
3.13
2.69
2.2
1.65
Total liabilities
27.1
26.9
28.1
37.6
38.4
35.9
25.8
7.41
8.31
13.4
Paid-in capital
81.1
104
108
207
282
288
304
335
347
451
Retained earnings
-72.1
-88.2
-106
-150
-174
-224
-289
-314
-332
-365
Other comprehensive income
-0.03
-0.03
-0.03
-0.03
-0.06
-0.21
-0.05
Shareholders' equity
8.91
16.2
2.46
56.6
109
63.5
15.4
21.3
14.9
85.7
Minority interests
0
-0
-0.01
-0.01
-0.02
Total equity
8.92
16.2
2.46
56.6
109
63.5
15.4
21.3
14.9
85.7
Total liabilities and equity
36
43.1
30.6
94.2
147
99.4
41.2
28.7
23.2
99.1
Shares outstanding
0.02
0.03
0.04
0.28
0.44
0.44
1.02
8.62
19.3
55.7
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-16.1
-16.1
-17.6
-16.4
-23.2
-50.3
-65
-24.9
-18.4
-33
Depreciation and amortization
1.33
1.37
0.18
0.28
0.47
2.28
0.67
0.64
0.48
0.56
Stock-based compensation
1.01
0.77
0.24
0.39
1.59
4.38
4.39
2.04
1.53
1.37
Deferred income tax
-12.8
-5.3
-8.54
-6.37
Change in receivables
0.31
0.04
-0.02
0.02
-0.43
-0.89
1
-0.07
Change in payables
-0.26
0.05
0.29
0.5
0.05
1.24
-0.63
-1.49
1.83
2.22
Cash from operations
-13.2
-13.5
-14
-13.3
-30.1
-37.5
-30.4
-18.6
-15.3
-23.2
Capital expenditures
-1.32
-0.93
-0.92
-1.08
-4.92
-7.33
-5.74
-0.21
-0.02
-0.58
Acquisitions
-0.69
Purchases of investments
-23.8
-5.36
-6.84
-42.3
Sales and maturities of investments
4
13.6
4.1
10.8
Cash from investing
-1.59
-1.08
-0.99
-1.15
-26.5
-5.13
7.01
0.91
0.74
-32
Stock issued
0
0
0.13
0.05
0.08
11.5
25.5
3.54
3.53
Cash from financing
-0.17
22.4
3.45
65.2
78.8
-6.13
2.3
24.5
8.93
103
Exchange rate effect
0
-0
-0
-0
-0
Net change in cash
-14.9
7.85
-11.5
50.7
22.3
-48.7
-21.1
6.85
-5.63
47.8
Free cash flow
-14.5
-14.4
-14.9
-14.4
-35
-44.8
-36.2
-18.8
-15.3
-23.8
Interest paid
1.93
1.92
1.9
2.37
2.45
1.05
0.69
0.75
0.21
0.07
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $1.19 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-35,141.0%
Operating income / revenue.
EBITDA margin
-34,583.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-33,044.0%
Pre-tax income / revenue.
Net margin
-33,044.0%
Net income / revenue.
FCF margin
-23,796.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-23,218.0%
Cash from operations / revenue.
Return on equity (ROE)
-65.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-54.0%
Net income / average total assets.
Return on invested capital (ROIC)
-155.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
19,643.0%
Research and development expense / revenue.
Stock-based pay / revenue
1,373.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
578.0%
Capital expenditures / revenue.
D&A / revenue
558.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-75.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
-46.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
476.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
77.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-4.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
327.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
34.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-7.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
891.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
454.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
205.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.85x
Current assets / current liabilities.
Quick ratio
7.50x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.50x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.32
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$0.23
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.22
Cash from operations / diluted weighted shares.
Book value per share
$1.54
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
591x
Market cap / revenue.
P/B
0.69x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.70x
Market cap / tangible book value, when positive.
FCF yield
-40.3%
Free cash flow / market cap.
Earnings yield
-55.9%
Net income / market cap (the inverse of P/E).
What was iBio, Inc.'s revenue in fiscal 2026?
iBio, Inc. reported revenue of $100.0K for fiscal 2026, 75% lower than the year before.
Was iBio, Inc. profitable in fiscal 2026?
No. It reported a net loss of $33.0M.
How much free cash flow did iBio, Inc. generate in fiscal 2026?
Cash from operations of $23.2M minus capital expenditures of $578.0K left free cash flow of -$23.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.